Impact of national pharmacare plan studied

November 1997
CMAJ: Canadian Medical Association Journal;11/15/97, Vol. 157 Issue 10, p1338
Academic Journal
Studies the release of findings on the cost of a fully funded, comprehensive and publicly administered national pharmacare program in Canada. The study by the Pharmaceutical Manufacturers Association of Canada; The cost of the program and the increase to public spending on prescription drugs; The consideration of the program by the federal government.


Related Articles

  • Federal agencies scrutinize pharmaceutical marketing, anticompetitive behavior. Wechsler, Jill // Formulary;Jan2003, Vol. 38 Issue 1, p62 

    Reports on developments related to government policy affecting the pharmaceutical industry in the U.S. as of January 2003. Compliance guidance for pharmaceutical companies issued by the U.S. Department of Health and Human Services in line with proposed Medicare pharmacy benefits for seniors in...

  • Winners and Losers in New Drug Innovation. DiMasi, Joseph A. // Medical Marketing & Media;Sep2001, Vol. 36 Issue 9, p98 

    Focuses on the drug innovations approved since the 1962 amendments to the Federal Food, Drug and Cosmetic Act in the U.S. Extent of innovative output concentration; Leadership position of major companies in research and development; Viability of merger strategy in establishing the market share...

  • Companies indicate support for PhRMA marketing code.  // Medical Marketing & Media;Jun2002, Vol. 37 Issue 6, p18 

    Focuses on the support of pharmaceutical companies for the marketing code of the Pharmaceutical Research and Manufacturers Association. Provision of training programs to educate employees on proper relations with physicians; Changes in the policy of companies; Benefits of the code for sales...

  • FDA overreached its authority in requiring pediatric tests.  // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p10 

    Reports on a U.S. federal district's decision that the Food and Drug Administration can (FDA) request but can never require companies to conduct studies of adult drugs on pediatric patients under existing law. Ruling that the FDA overreach its statutory authority under the Pediatric Rule;...

  • HHS guidance reinforces current positions, warns of increased oversight.  // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p22 

    Reports on the issuance of Draft Compliance Program Guidance for Pharmaceutical Manufacturers in the United States. Contents of the guidelines; Objectives.

  • Harmonization at home and abroad. Wechsler, Jill // Pharmaceutical Executive;Jun98, Vol. 18 Issue 6, p18 

    Deals with the guidelines for the uniform development of medications in the United States finalized at the International Conference on Harmonization (ICH). Impetus for the harmonization of inspections and enforcement actions of United States Food and Drug Administration; Benefits of adherence...

  • Untitled.  // Pharmaceutical Executive;Sep99, Vol. 19 Issue 9, p176 

    Presents articles pertaining to the pharmaceutical industry in the United States (US). Marketing approval in Europe obtained by Sanofi-Synthelabo for Eloxatine (oxaliplatin), a first-line treatment for metastatic colorectal cancer; Move of the Food and Drug Administration (FDA) in approving...

  • Can payers afford to watch and wait? Pavlou, Fedra // Pharmaceutical Technology Europe;Aug2010, Vol. 22 Issue 8, p6 

    An introduction to the journal is presented in which the editor discusses the interest of biopharmaceutical industries in developing biosimilar medicines, the complex regulatory environment for biosimilars, and the initiative of the European Generic Medicines Association to improve access to...

  • Starting Material, Processing, Retesting, and Critical Controls. Cupps, Tom; Fritschel, Betsy; Mavroudakis, Wendy; Mitchell, Michael; Ridge, Dave; Wyvratt, Jean // Pharmaceutical Technology;Feb2003, Vol. 27 Issue 2, p34 

    Provides perspectives and recommendations from the Pharmaceutical Research and Manufacturing Association of America (PhRMA) on drug substance regulatory filing issues. Starting-material definition, reprocessing, retest practices, and control of critical controls; Examination of the revisions...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics